Insmed Incorporated (INSM)

NASDAQ: INSM · IEX Real-Time Price · USD
27.13
-0.19 (-0.70%)
At close: Mar 28, 2024, 4:00 PM
26.27
-0.86 (-3.17%)
After-hours: Mar 28, 2024, 5:52 PM EDT

Company Description

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.

The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.

It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension.

The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Insmed Incorporated
Insmed logo
Country United States
Founded 1988
IPO Date Jun 1, 2000
Industry Biotechnology
Sector Healthcare
Employees 912
CEO William H. Lewis J.D., M.B.A.

Contact Details

Address:
700 Us Highway 202/206
Bridgewater, New Jersey 08807
United States
Phone 908-977-9900
Website insmed.com

Stock Details

Ticker Symbol INSM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001104506
CUSIP Number 457669307
ISIN Number US4576693075
Employer ID 54-1972729
SIC Code 2834

Key Executives

Name Position
William H. Lewis J.D., M.B.A. President, Chief Executive Officer and Chairman
Sara M. Bonstein M.B.A. Chief Financial Officer
Roger Adsett M.B.A. Chief Operating Officer
John Drayton Wise M.B.A. Chief Commercial Officer
Dr. Martina Flammer M.B.A., M.D. Chief Medical Officer
Brian K. Kaspar Ph.D. Chief Scientific Officer
Eleanor Barisser Associate Director of Investor Relations
Michael Alexander Smith J.D. Chief Legal Officer and Corporate Secretary
Mandy Fahey Executive Director of Corporate Communications
S. Nicole Schaeffer M.B.A. Chief People Strategy Officer

Latest SEC Filings

Date Type Title
Mar 11, 2024 8-K Current Report
Feb 22, 2024 8-K Current Report
Feb 22, 2024 424B5 Filing
Feb 22, 2024 10-K Annual Report
Feb 16, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 25, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 22, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals